Patent · US Active

Peptide PAC1 antagonists

US11643440B2 · kind B2 · utility

0Cited by

5References

4Claims

0Family size

Assignee

AMGEN INC. · US

Inventors

Irwin Chen · Moreno Valley, US
Su CHONG · Oxnard, US
Essa Hu Harrington · Camarillo, US
Fang-Tsao Hong · Thousand Oaks, US
Jason C. LONG · Newbury Park, US
Leslie P. Miranda · Thousand Oaks, US

Key dates

Filing date	Jun 1, 2018
Grant date	May 9, 2023
Priority date	—
Expiry date	Jun 1, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.